Arcus Biosciences Inc. Stock News

Arcus Biosciences, Inc. (NYSE:RCUS) General Counsel Carolyn C. Tang sold 487 shares of the firms stock in a transaction dated Thursday, December 16th. The shares were sold at an average price of $39.82, for a total value of $19,392.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible []

Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced the closing of Gileads option exercises to three progra

Parametric Portfolio Associates LLC trimmed its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 14.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 29,772 shares of the companys stock after selling 4,873 shares during the quarter. Parametric Portfolio []

Wall Street brokerages expect Arcus Biosciences, Inc. (NYSE:RCUS) to post sales of $8.87 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Arcus Biosciences earnings, with estimates ranging from $8.10 million to $9.50 million. Arcus Biosciences posted sales of $9.49 million in the same quarter last year, which would []

Arcus was one of the few winners in the turbulent biotech space last month.

Brokerages predict that Arcus Biosciences, Inc. (NYSE:RCUS) will report ($1.13) earnings per share for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Arcus Biosciences earnings. The highest EPS estimate is ($1.09) and the lowest is ($1.17). Arcus Biosciences reported earnings per share of ($0.82) during the same quarter last year, []

Arcus Biosciences Inc. (NYSE:RCUS) has a beta value of 0.95 and has seen 1.08 million shares traded in the last trading session. The company, currently valued at $2.82B, closed the last trade at $43.80 per share which meant it lost -$1.32 on the day or -2.93% during that session. The RCUS stock price is -12.1% Arcus Biosciences Inc. (RCUS) Has A Bright Growth Prospects For 2021 Read More »

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, and Taiho Pharmaceutical Co., Ltd., (Taiho), an R&D driven specialty pharma company with a focus on oncology, today announced that Taiho exercised its option for anti-TIGIT antibodies domvanalimab (development code: AB154) and AB308 from Arcus Biosciences (Arcus), in Japa

Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.

Wall Street analysts forecast that Arcus Biosciences, Inc. (NYSE:RCUS) will announce earnings per share of ($1.13) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Arcus Biosciences earnings, with the highest EPS estimate coming in at ($1.09) and the lowest estimate coming in at ($1.17). Arcus Biosciences posted earnings []

Arcus Biosciences Inc (RCUS) shares closed today at 1.3% below its 52 week high of $49.10, giving the company a market cap of $3B. The stock is currently up 86.7% year-to-date, up 88.2% over the past 12 months, and up 185.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.2%. Trading Activity Trading volume this week was 25.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -387.5% The company's stock price performance over the past 12 months beats the peer average by -447.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate in a fireside chat at the upcoming Evercore ISI HealthCONx 2021 Conference. The fireside chat will take place on Wednesday, December 1st, 2021 at 4:20 p.m. ET. A live audio webcast of the fireside chat will be available by visiting the

Could these biotech stocks be poised for long-term gains?

Arcus Biosciences, Inc. (NYSE:RCUS) was up 4.8% during trading on Friday after Wedbush raised their price target on the stock from $52.00 to $67.00. Wedbush currently has an outperform rating on the stock. Arcus Biosciences traded as high as $45.62 and last traded at $45.62. Approximately 2,984 shares were traded during trading, a decline of []

Arcus Biosciences (NYSE:RCUS) had its target price upped by Wedbush from $52.00 to $67.00 in a report published on Friday morning, The Fly reports. They currently have an outperform rating on the stock. A number of other analysts have also recently commented on the company. SVB Leerink upped their price objective on Arcus Biosciences from []